glp 1 naion Semaglutide Network Study Announcement Smaller NAION Risk with Semaglutide
Description
Without lifestyle changes, weight regain is common after discontinuing GLP-1 receptor agonists
Thyroid Cancer: As with other GLP-1 medications, animal studies have shown a theoretical risk of thyroid tumours
The inconsistent results may be due to the low incidence and the incorporation of studies with limited sample sizes, statistical effectiveness was not greatly increased
A February 2026 study found an 11% higher fragility fracture risk in GLP-1 users in a specific diabetic population
PMC Xie X, et al
Can a pharmacist prescribe antibiotics
